0001826457false00018264572024-06-122024-06-12

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2024

MONTE ROSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40522

84-3766197

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

321 Harrison Avenue, Suite 900

Boston, MA, 02118

(Address of principal executive offices, including zip code)

(617) 949-2643

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share

GLUE

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to Vote of Security Holders

On June 12, 2024, Monte Rosa Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2024, the record date for the Annual Meeting, there were 50,325,324 outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The Company’s stockholders voted on the following matters, which are described in detail in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”): (i) to elect two directors, Markus Warmuth, M.D. and Ali Behbahani, M.D., as Class III directors of the Company, each to serve for a three-year term expiring at the Company’s 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

Proposal 1 - Election of Class III Director Nominees

The stockholders of the Company elected Markus Warmuth, M.D. and Ali Behbahani, M.D. as Class III directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2027 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:

 

 

Votes
For

 

Votes
Withheld

 

Broker
Non-Votes

Markus Warmuth, M.D.

 

39,473,886

 

84,415

 

910,598

Ali Behbahani, M.D.

 

23,794,947

 

15,763,354

 

910,598

Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:

 

Votes

 

Votes

 

 

 

Broker

For

 

Against

 

Abstain

 

Non-Votes

40,409,003

 

59,893

 

3

 

0

 

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

Monte Rosa Therapeutics, Inc.

 

 

 

 

Date: June 12, 2024

 

By:

/s/ Markus Warmuth

 

 

 

Markus Warmuth

 

 

 

President and Chief Executive Officer

 

 

v3.24.1.1.u2
Document And Entity Information
Jun. 12, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001826457
Document Type 8-K
Document Period End Date Jun. 12, 2024
Entity Registrant Name MONTE ROSA THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40522
Entity Tax Identification Number 84-3766197
Entity Address, Address Line One 321 Harrison Avenue
Entity Address, Address Line Two Suite 900
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02118
City Area Code (617)
Local Phone Number 949-2643
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol GLUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Grafico Azioni Monte Rosa Therapeutics (NASDAQ:GLUE)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Monte Rosa Therapeutics
Grafico Azioni Monte Rosa Therapeutics (NASDAQ:GLUE)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Monte Rosa Therapeutics